A Silicon Valley start-up with some big-name backers is threatening to upend genetic screening for breast andovarian cancer by offering a test on a sample of saliva that is so inexpensive that most women could get it.
At the same time, the nation’s two largest clinical laboratories, Quest Diagnostics and LabCorp, normally bitter rivals, are joining with French researchers to pool their data to better interpret mutations in the two mainbreast cancer risk genes, known as BRCA1 and BRCA2. Other companies and laboratories are being invited to join the effort, called BRCA Share.